– USA, WA – Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of Natasha Hernday to its Board of Directors, bringing more than 20 years of experience in corporate development and corporate strategy.
“I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Executive Chairman and CEO, Dr. Mitchell Gold. “I look forward to benefiting from Natasha’s extensive experience and acumen as we oversee the next stages of Alpine’s growth to the benefit of Alpiners, shareholders and patients alike.”
The company also announced that Paul Sekhri will be stepping down as a director of the company, having served on the Board of Directors since February 2016.
Dr. Mitchell Gold commented, “On behalf of the Board and Alpine’s executive team, I would like to thank Paul for the service he has provided to the company and wish him well in any future endeavors.”
About Natasha Hernday
Ms. Hernday currently serves as EVP, Corporate Development, and as a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. (NASDAQ: SGEN). Since joining Seagen in 2011, Ms. Hernday has built and led the business development team responsible for licensing deals, acquisitions, and strategic alliances. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers & Acquisitions, and as Director, Out-Partnering. She also serves on the board of directors of Xoma Corp. (NASDAQ: XOMA) and PDL BioPharma, Inc. (NASDAQ: PDLI), and the Knight Campus External Advisory Board for the University of Oregon.
Ms. Hernday received her BA in microbiology from the University of California at Santa Barbara and an MBA from Pepperdine University.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly-productive scientific platform, and a proven management team, Alpine is creating multifunctional immunotherapies via unique protein engineering technologies designed to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.
For more information: https://www.alpineimmunesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
